| abstract |
In one aspect, the present invention relates to a pharmaceutical composition comprising iduronate-2-sulfatase beta (IDS-β), which may be administered into the cerebral lateral ventricle once every four weeks to treat Hunter syndrome in a subject. Compared to a single administration of the same dose of an active substance, the present invention, due to repeated administrations over a long period of time, exhibits superior effects in treating Hunter syndrome, and further has the following effects which cannot be anticipated from the result of a single administration: treating or restoring a damaged brain structure; and substantially treating or improving brain functions, particularly, improving memory and learning. |